Immunization against hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 MCG).

Abstract

A previous seroepidemiological study in the rural zone of Vargem Alta (ES) SouthEast of Brazil, showed a prevalence of up to 9% of hepatitis B surface antigen (HBsAg) in some areas. One hundred susceptible children aging 1 to 5 years old were selected and immunized with a recombinant DNA hepatitis B vaccine (Smith-Kline 20 mcg) using the 0-1-6 months vaccination schedule. Blood samples were collected at the time of the first vaccine dose (month 0) in order to confirm susceptible individuals and 1,3,6 and 8 months after the first dose, to evaluate the antibody response. Our results showed that two and five months after the second dose, 79% and 88% of children seroconverted respectively, reaching 97% after the third dose. The levels of anti-HBs were calculated in milli International Units/ml (mIU/ml) and demonstrated the markedly increase of protective levels of antibodies after the third dose. These data showed a good immunogenicity of the DNA recombinant hepatitis B vaccine when administered in children of endemic areas.

Cite this paper

@article{Ferreira1993ImmunizationAH, title={Immunization against hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 MCG).}, author={Cristiana R. Ferreira and Clara Fumiko Tachibana Yoshida and Luciano Allegretti Mercadante and Daniela Fichtner Gomes and Joyce Moura Oliveira and Marcelo França and Maria D Sidoni and Ilka Ennes and Marcia Leite Baptista and Hermann Gonçalves Schatzmayr}, journal={Revista do Instituto de Medicina Tropical de São Paulo}, year={1993}, volume={35 1}, pages={89-92} }